Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US.

Kimberly R SavernoKristin M Zimmerman SavillCherrishe Brown-BickerstaffAngele KotomaleMichael RodriguezBruce FeinbergHaobo RenMike BleckerRichard D Kim

Published in: The oncologist (2024)

This study complements the FIGHT-202 clinical trial by assessing the use of pemigatinib among a diverse population of patients with CCA under real-world conditions. Findings support the clinical benefit of pemigatinib demonstrated in FIGHT-202.

Keyphrases

clinical trial
randomized controlled trial
phase ii
double blind
phase iii